r e v i e w quantification accuracy 21 . However, methodological advances in the analysis of amino acids have lagged compared to the rapid innovations in nucleic acid sequencing. Our inability to amplify amino acids in vitro-there is no PCR for protein-leads to more demanding technical requirements for protein detection. Despite this limitation, it is now possible to reliably obtain quantitative observations for tens of thousands of peptides derived from up to 10,000 proteins per sample 22 , and important steps have been taken very recently toward profiling the entire human proteome 23, 24 .
Given the critical insight into the biosynthetic state of the cell offered by proteins and their modifications, whole-proteome analysis is a necessity for investigators studying all aspects of complex organisms, especially the brain. Mass spectrometry remains the only method of profiling the neuroproteome with a throughput and resolving power comparable to those of other functional genomic methods 25 . Quantitative analysis of the thousands of proteins expressed in each of the probably hundreds of distinct neuronal cell types is vital for a deeper understanding of the functional anatomy and systemlevel functions of CNS cells. Integration of proteomics with other functional genomic data is also necessary to better understand the dynamics of RNA and protein expression, the roles of posttranslational modifications and the trafficking of molecules within neurons and glia.
In this Review, we first discuss the advantages of increased adoption of mass-spectrometry proteomics within the context of the multiomic approaches currently used to profile molecules of the CNS. We then offer a brief perspective on how the field can benefit from deeper integration of proteomic and functional genomic analyses. Finally, we discuss approaches to achieving cell-type specificity in omic analyses and how these can be improved to better serve the needs of the neuroscience community, especially with respect to interpreting results in the framework of the functional anatomy of the brain.
Biological insights from mass spectrometry-based proteomics
The various methodologies available for proteomic profiling have been covered comprehensively elsewhere, including excellent reviews on mass-spectrometry technologies 19, 26 , analysis 27 and interpretation 28, 29 and specific examples of proteomics applied to the CNS 30 . The primary insights offered by mass-spectrometry proteomics are the sequences, post-translational modifications (PTMs) and abundances of up to tens of thousands of peptides and/or proteins in a given sample. The various methods available for spectra acquisition and quantification can be complemented by purification of proteins from distinct subcellular compartments, which allows investigators to specifically and separately assay proteins located in the nucleus, cytosol, cytoskeleton, endoplasmic reticulum and plasma membrane 31 . Increased subcellular resolution combined with mass spectrometry can improve the dynamic range and sensitivity to low-abundance or membrane-specific proteins that may otherwise be occluded by highly abundant nuclear and cytosolic proteins 32 . Extending beyond comparisons of steady-state protein expression, metabolic labeling of amenable cells (for example, in culture) is capable of yielding valuable insights into rates of protein turnover and has revealed that proteins are both more abundant and have a longer half-life than RNAs 33 .
Besides being the ultimate molecular readout of the genome, the proteome contains a wealth of information about the landscape of well over 90,000 sites of PTM that are simply inaccessible through the analysis of nucleic acids 34 . Studies of dynamic cellular processes involving protein kinases and phosphatases-regulatory enzymes that are responsible for signal transduction-provide valuable insight into the regulation of protein function 35 . In addition to phosphorylation, PTMs such as acetylation, acylation, deamidation, glycosylation, methylation and ubiquitination have pivotal roles in regulating almost all cellular processes, including energy production and transport, DNA modification, transcription and translation of RNA, and RNA or protein stability 36 . This information is obtained directly by mass spectrometry from the characteristic mass shift that these modifications cause in the peptide spectra and, as such, provides not only the exact locations of these modifications but also measurements of their relative abundances. For example, mass spectrometry has been a valuable tool for locating PTMs implicated in CNS development 37 and disorder 38 , including interrogating specific hypotheses such as p300-mediated acetylation of Tau 39 and regulation of the transcriptional repressor LSD1 through phosphorylation 40 . Peptide sequence and PTM data can also be obtained from specific subcellular fractions to profile, for example, the fascinating landscape of histone modifications, including simultaneous analysis of the co-occurrence of various combinations of histone marks 41 . Further, proteomic profiling of the nucleus has enabled simultaneous quantification of the complete set of expressed transcription factors and has been vital in identifying new regulatory proteins 42 .
Integration of proteomic, transcriptomic and genomic data
The wealth of information available from proteomics is complemented by insights offered by other functional genomic assays, such as next-generation RNA sequencing (RNA-seq). However, it is common for studies to focus on just one of these data modalities. There are major benefits to studying multiple layers of a system using the various functional omic methods, but to obtain maximum utility, the generated data need to be carefully integrated. For example, the integration of DNA variants and chromatin signals with transcriptomics has been extremely valuable for gaining a deeper intuition for genetic, epigenetic and post-transcriptional regulation in the CNS 43, 44 (see also http://brainspan.org/). Integration of transcriptomic and proteomic data has the potential to be just as powerful for monitoring the often-subtle effects or dysfunction of protein production and localization underlying neurodevelopment and neuropathology. Most efforts to combine transcriptomic and proteomic profiling have compared or validated the expression of genes using the abundance of their RNAs and proteins, including characterization of abundances across healthy tissues 45 , changes due to neurological disorders 46 and localized expression in neuronal processes 47 . An additional major attraction of proteomics lies in peptide sequences, which enable proteomewide validation of genomic and transcriptomic variants, allelic imbalance and isoform identification 22 (Fig. 1) . We briefly discuss various levels of analysis at which complementary proteomic data are required, suggest strategies whereby genomic and transcriptomic data can be better integrated and highlight the potential advantages of such approaches in studies of the CNS.
Understanding the translatome and translational efficiency Several high-quality studies have employed mass spectrometry to profile the protein output of tissues and organisms and have been useful as standalone resources 23, [48] [49] [50] . Mass-spectrometry experiments have also been performed as validations for findings obtained by chromatin or RNA profiling 51 , and occasionally, RNA-level data have been used as a reverse validation of results obtained by mass spectrometry 52 . Although often presented as being 'integrated' , such validation-driven analyses tend to provide limited additional insight, instead serving as a secondary mechanism for controlling the rate of false discoveries in the original experiment; however, there are some recent examples of deliberate multilevel omic analyses in neuroscience 53 . Given the npg r e v i e w tremendous volumes of data that can be produced by mass spectrometry and other functional genomic assays, now more than ever there exist major analytical advantages to designing studies combining transcriptomic and proteomic data 22 .
Importantly, those studies that have attempted deliberate coanalysis of RNA and protein have consistently observed a limited correlation (between 0.5 and 0.7) in abundance. As such, measurements of mRNA abundance alone are insufficient to be considered predictive of protein abundance [54] [55] [56] , reinforcing the requirement for cellular analysis at the proteome level. The cause for this poor correlation is probably a combination of biological and technical factors 57 , where such biological factors include cellular heterogeneity, alternative splicing, post-transcriptional regulation, post-translational modifications, protein turnover and protein localization. It is therefore essential for our deeper understanding of cellular mechanics, especially in highly heterogeneous tissues such as those of the CNS, to minimize technical variability so that samples subjected to multi-omic analysis are of high quality, inherently comparable and processed with consistency.
A promising recent innovation allows direct profiling of the translatome, or the set of actively translating RNAs engaged by the polyribosome, thus enabling analysis of RNA at a point closest to the production of protein 58 (we discuss so-called RiboTag or TRAP methods and their utility in the CNS below). A more detailed assessment of translational control 59 can be obtained by sequencing the very short fragments of RNA contained within the ribosome itself 17 . So-called ribosome profiling allows, for the first time, a transcriptome-wide survey of the positions of ribosomes on the RNA transcript, including precise identification of open reading frames. When compared to the relative abundance of those same transcripts, the approach has formalized the concept of translational efficiency, a mechanism through which cells may have the ability to modify protein output while maintaining stable RNA abundance simply by increasing the Create personal genome using variants and CNV
Create personal transcriptome using variants, splicing and abundance
Create personal proteome using variants, abundance and PTMs Figure 1 Integrated genomic, transcriptomic and proteomic analyses and the central dogma. (a-c) Illustrated are the three canonical processes of the central dogma, the common methods by which genome-wide data are obtained and the information provided by these data. (a) Whole-genome or exome sequencing provides genomic variant information. An example multi-exon gene is annotated with two isoforms, differentiated by a skipped penultimate exon, and contains several nonsynonymous mutations identified by whole-genome sequencing, exome sequencing or genotyping microarray (SNPchip). Each homozygous or heterozygous missense mutation causes a change in the codon at its respective position, and a nonsense mutation leads to a premature stop codon in the penultimate exon of the first isoform. (b) These mutations are reflected in the maternal (m) and paternal (p) transcripts produced for each isoform and are detected in the reads obtained from RNA-seq, which also detects an RNA-edit site in all transcripts. RNA-seq quantification reveals that the second isoform is predominantly expressed based on the subset of reads (red) that are able to distinguish the first from the second isoform. Also evident from the quantification is that the maternal transcript of isoform 2 is primarily expressed (ASE) based on a different subset of reads that span the heterozygous variant. (c) Whole-proteome analysis by mass spectrometry produces spectra that can be matched against a database derived from the maternal and paternal transcripts and also produces peptides that span the positions of the homozygous and heterozygous variants. The abundances of these peptides support the RDD and allelic bias observed in RNA-seq. The spectra also suggest the presence of a post-translational modification, and the absence of peptides toward the C terminus of the first isoform lead, for example, to the inference that no protein is produced for this isoform. UTR, untranslated region; CNV, copy-number variants; AS, alternative splicing; LC-MS/MS, liquid chromatography-tandem mass spectrometry; NMD, nonsense-mediated decay.
npg r e v i e w density of ribosomes on selected transcripts 60 . This has substantial consequences for the integration of proteomic and transcriptomic analyses and should provide a more reliable predictor of protein abundance than simple RNA expression, once the methodology matures 59 . Ribosome profiling of the CNS is currently in its infancy, mainly because of limitations arising from the amount and quality of input RNA. However, an initial study of brain tumor material has suggested for the first time that despite an apparent overabundance of certain mRNAs in brain tumors, the translational efficiency of these genes is very low compared to non-tumor specific genes 61 . Ribosome profiling has also shown that long noncoding RNAs in the cytosol, many of which are known to be spliced, capped and polyadenylated in a manner similar to mRNAs 62 , can be engaged by the polyribosome 56 but do not code for proteins 63 . In a somewhat related manner to ribosomal profiling, it is possible to assay the production and degradation of polypeptides at the protein level by either pulse-labeling SILAC (stable isotope labeling by amino acids in cell culture) proteomics 64 or the capture of nascent peptide chains as they are synthesized by the ribosome using biotin-puromycin labeling 65 . However, these approaches have rather limited application in studying intact organisms and tissues such as the brain because of the requirement of invasive chemical labeling.
Proteomic assessment of alternative splicing and isoform usage
Alternative splicing is a highly tissue-specific process 18 that greatly increases the complexity of the potential set of RNA molecules produced from multi-exon genes. Splicing in the brain has been profiled extensively using transcriptomics, and specific instances of alternative transcript usage have been implicated in neuropsychiatric disorders 11 . During CNS cell development, for example, alternative splicing in neuronal progenitor stem cells has revealed differential isoform usage at different stages of maturation 66 . Extensive profiling of alternative splicing has characterized the expression of DISC1 isoforms that are associated with schizophrenia 67 . Validation of splicing events by mass spectrometry is feasible (Fig. 1) , in terms of either determining the abundances of known isoforms in a given cell type or verifying the existence of new exon junctions identified by RNA-seq 68 , but has not yet been systematically applied to the CNS. Proteomics may be useful, for example, in determining whether the DISC1 translocation in schizophrenia encodes a protein product 69 .
A recent result that has a potentially important impact on the interpretation of proteomic data is the finding that most genes in a given cell type probably express only a single dominant transcript 70, 71 . This finding has direct consequences for differential isoform usage between CNS cell types and for the progression of neurological disorders affecting protein-protein interactions, as exemplified in the Autism Spliceform Interaction Network 72 . Currently, full-length transcript 73 and isoform 74 profiling technologies are immature 75 but have great potential. For example, full-length RNA profiling in the brain has been exploited to observe directly the various isoforms of neurexin, showing that their production mediates distinct protein interactions at the synapse 76 .
Proteomic confirmation of genomic and transcriptomic variants RNA editing, also referred to as RNA-DNA differences (RDDs), appears to have had a major role in human brain evolution 16, 77 , and of the trio of ADAR proteins responsible for the post-transcriptional alanine-to-isoleucine modification, ADAR3 is expressed exclusively in the brain 16 . Several missense RDDs in the AMPA receptor are edited at specific stages of human brain development 78 and are required for normal brain function and phenotypes in mice 79 .
The serotonin receptor 5-HT 2C R contains numerous RDDs that both alter the expressed protein sequence 80 and cause an order-of-magnitude reduction in efficacy in the interaction of the receptor with its G proteins 81 . Unfortunately, reliable identification of RDDs is technically challenging, which has led to false-positive identifications 82 . Mass spectrometry is therefore an extremely attractive tool for unbiased validation of missense RDDs and for providing quantification of edited and unedited copies of the proteins.
Within a given individual, the allele-specific expression (ASE) of an RNA or protein can be the result of epigenetic regulatory processes that are common across species and tissues 83 . Detection of ASE relies on the discovery of heterozygous genomic variants that allow for monitoring imbalances in the abundance of RNA produced from each parental allele, with missense (nonsynonymous) variants enabling detection of ASE by mass spectrometry 84 . A recent survey of the mouse CNS revealed 1,300 ASE transcripts that favor the maternal allele during brain development, whereas in the adult brain, the bias shifts toward the paternal allele 85 . Mass spectrometry has also been used to identify and assess levels of allele-specific transcription factor binding and define allelic regions of the genome that are associated with disease 86 . Such analyses are appealing because of potential cascade effects caused by ASE or allele-specific transcription factor binding; for example, differential expression or activity of an allelic transcription or splicing factor may have a substantial impact on downstream cellular processes.
Quantitative trait loci (QTLs) have been mapped extensively to a variety of complex traits using transcriptomics in terms of the relationship between genomic variants and RNA expression, and more recently, variants have also been related to protein abundance (pQTLs) 87 . In the prefrontal cortex, for example, such variants reportedly affect the expression of more than 100 genes 88 . An analysis of individuals genotyped in the HapMap project reported that almost two-thirds of 185 observed cis-acting pQTLs were not found in a complementary analysis of RNA 89 . An example pQTL that was not detected in the RNA-level analysis lies in the 3′ untranslated region of the IMPA1 gene, a putative target for lithium 90 , and may be responsible for the post-transcriptional regulation of expression of the gene. In this way, mass-spectrometry proteomics has the power to meaningfully complement RNA analysis in the detection and functional characterization of phenotype-associated genomic variants.
There has been a flurry of recent activity in identifying and ascribing potential functional roles to fusion transcripts and non-protein coding regions of the genome. Efforts, including those of ENCODE 71 and others 91 , have reported that more than 75% of genomic DNA is at some point transcribed to primary (unspliced) RNA. This idea of pervasive transcription has caused some controversy and confusion, not least of which when considering whether the production of these RNA molecules may imply that they have a functional role in cellular processes. Transcriptomic analysis alone is therefore insufficient to accurately define the cohort of protein-coding sequences, even when combined with ribosome profiling, and predictions must be refined using high-throughput proteome profiling.
Improving compatibility of proteomics with functional genomics Improvements to encourage the integration of proteomics with other data fall into three main areas: annotation, archival and methodology.
Annotation improvements. These include consistent sequence annotation among the functional genomics. A basic but important limitation of annotation is that different gene annotations are often npg r e v i e w used in the analysis of RNAs and proteins. Adoption of a high-quality proteome annotation that is consistent with genomic databases such as ENSEMBL or UCSC would not only improve RNA and protein abundance comparisons but would also facilitate the integration of peptide and protein abundance to genome browsers.
Archival improvements. These comprise, in part, improved protein sequence databases. High-quality integration depends on equally high-quality data made available in well-curated and well-maintained online repositories. Databases of peptide identifications such as Proteomics Identifications (PRIDE) 92 and the Peptide Atlas 93 are valuable resources for mapping spectra on the basis of previously identified peptides; however, they are of limited use to nonexperts who may simply desire higher-level information about proteins observed in a given disease state, tissue or cellular compartment 94 . The neuroscience community would benefit from a large-scale resource providing quantitative data on peptide or protein abundance to complement the wealth of RNA expression data obtained from the human brain 8, 10 . Proteomic databases exist for plant species 95 and, more recently, human tissues 9, 23 , but public data on protein localization and abundance across the brain are currently far less mature than their RNA equivalents. A combined resource containing peptide identification and quantification data and transcriptomics would be extremely valuable and may provide a framework with which to tackle open questions in proteomics, such as alternative splicing and the nonuniform peptide coverage of proteins.
Methodological improvements. These comprise, in part, more consistency in spectra data analysis between mass-spectrometry platforms. The Human Proteome Organization (HUPO) Brain Proteome Project (BPP) recommends disseminating mass-spectrometry data in the form of lists of identified spectra and corresponding peptide sequences 96 . However, the software and choice of parameters for peak picking, peptide identification, PTM identification and quantification remains a major source of information loss and variability 97 , and the use of software is often dependent on the vendor. Dissemination of the raw spectra will be required for reanalysis of published data and to facilitate development of open-source analysis software. Methodological improvements also include experimental and computational assessment of the translatome. The primary goal for more effective integration of transcriptomics and proteomics should be to capitalize on experimental methodologies, such as ribosome profiling, single-molecule RNA-seq and top-down mass-spectrometry profiling of intact proteins, as well as computational methods that maintain an awareness of upstream information during the analysis of spectra. Utilizing ribosome footprinting, for example, to identify coding sequences and translation initiation sites has been shown to produce moderately increased rates of peptide identification in the same samples 98 . Additionally, there has been some recent interest in leveraging sequence variants obtained from RNA-seq to improve peptide identification 99, 100 , which have in turn resulted in the production of somewhat basic software tools for the integration of such data sets 101 . A conceptual framework in which to achieve complete integration of proteomic and functional genomic analyses is offered in Box 1 and Figure 1 .
Challenges in assessing the proteome(s) of the CNS
The many high-quality proteomic studies of the CNS have been enumerated in previous reviews 30, 102, 103 . Recent examples include profiling neural tissues in zebrafish 104 , cultured neurons 105 and oligodendroglial cells 106 . However, most neuroproteomic studies are inherently limited by their implicit interrogation of protein expression or modification in mixed populations of neuronal cell types. This limitation results from the distinct transcriptional profiles of intermixed neuronal and glial cell types, as well as the short-and longer-term regulatory processes initiated by differential expression of neurotransmitter and neurotrophic factor receptors. Existing whole-tissue analyses 10 , even when combined with careful manual dissection, are not sensitive to intercellular or intracellular variability, and as a result, functional genomic information is diluted among the different classes of intermixed neurons and the high proportion of glial cells. Therefore, the key to overcoming this cellular heterogeneity lies in experimental approaches to deconvolve the multitude of cell types by purifying or selecting a single cell type before functional genomic or proteomic analysis.
Current approaches to overcoming intercellular and intracellular heterogeneity When pondering the variety of options for profiling individual cell types in a complex tissue, there is a strong temptation to wish for technological and methodological developments to converge on the profiling of single cells. This level of analytical detail will be revolutionary in terms of additional power to resolve changes in molecular abundance during, for example, neuronal differentiation from progenitor cells. However, there exist drawbacks to currently available methods of single-cell analysis 107 . An obvious limitation is that multimodal profiling of the same single cell is currently impossible, and as such, regulatory relationships between the dynamics of RNA transcription, regulation and translation would still need to be inferred rather than observed directly. Additionally, the throughput and resolving power of single-cell approaches are still too low to meaningfully assess the responses of collections of neurons in a given brain region to experimental conditions such as the chemical effects of a drug, especially when there is a requirement for multiple biologically independent subjects. There is no doubt that with the continued development of sequencing and mass spectrometry-based methods for low sample input, new and exciting biology will emerge that advances our understanding of transcriptional and translational programs both within the cell and in cell-to-cell signaling 108, 109 .
Similarly, the analysis of single or small numbers of neural cells, obtained, for example, by laser-capture microscopy (LCM), followed by transcriptional and proteomic profiling is an attractive approach, as it enables molecular quantification in a well-defined physical volume of tissue. However, isolating neuronal cells by LCM is a time-consuming process and is not guaranteed to result in cell-type specificity because of cellular proximity and overlapping processes. In addition, current proteomic technologies require two to three orders of magnitude more cells-compared to an equivalent analysis of RNA-to be collected by LCM to obtain sufficient material to begin to interrogate their proteome. A potential solution may be application of mass cytometry to measure tens to hundreds of proteins in single cells at subcellular resolution; however, low throughput currently limits this technique 110 .
Fluorescence-activated cell sorting (FACS) is a very flexible method for separating and purifying populations of cells, typically using panels of selective antibodies. Purification of mouse microglia by FACS with an antibody to P2ry12, a glia-specific surface protein, has revealed over 100 genes that are enriched compared to in neurons and other oligodendrocytes 53 . FACS has also enabled analysis of mouse synaptic proteins by mass-spectrometry proteomics after overexpression of a GFP-tagged VGLUT1 (also called SLC17A7) transgene 111 . Despite the success of this sorting for the purification of more npg r e v i e w granular cells such as glia, these sorting methods suffer in a manner similar to LCM when dealing with mature neurons because of loss of their extensive axonal and dendritic processes. A new variant of FACS, fluorescence-activated nuclei sorting, has been used recently to bypass the incompatibility of neurons with whole-cell sorting. For example, antibody labeling using the neuronal-specific splicing protein NeuN was used to purify neuronal nuclei from primary tissue to provide a quantitative comparison of the abundance of nuclear proteins with astrocytes and oligodendrocytes 112 . Additionally, purification of striatal nuclei by NeuN labeling has led to interesting observations of adult human neurogenesis in the hippocampus 113 and striatum 114 . The full complement of nuclear proteins, specifically histones and transcription factors, is thus accessible for neuron-specific massspectrometry analyses.
Beyond the nucleus, the subcellular localization of RNAs and proteins is fundamental for neuronal development, function and disease 115 . The abundance of proteins localized, for example, at the presynapse and postsynapse and reflected in the content of subcellular fractions such as the postsynaptic density is dependent on cell type and brain region [116] [117] [118] . Because of various confounders introduced by the trafficking of proteins and RNAs and/or local translation at synapses (or, potentially, in axons) 115 , proteomic profiling of enriched synaptic fractions can provide greater sensitivity and specificity than transcriptomics in assessing the molecular regulation of synaptic proteins. The application of density gradient centrifugation for the purification of other subcellular fractions, such as the plasma membrane or lipid rafts, or of specific types of organelles, such as mitochondria of the Golgi, offers subcellular resolution 31 , but the familiar issue of intermixing of multiple cell types remains an important barrier to the utility of this approach in the CNS.
A molecular approach to high-throughput analysis with cell-type specificity An extremely elegant means of obtaining quantitative expression measurements for a specific gene from a specific cell type is through the creation of libraries of bacterial artificial chromosomes containing fluorescent marker proteins downstream of target regulatory elements (enhancers or promoters) that lie upstream of the desired gene 13 . Such an approach, when collected for multiple regulatory elements or when used in combination with in situ hybridization and/or immunohistochemical spatial expression profiles, has been extremely successful in revealing cell type-specific promoter activity and RNA expression 119 . A complementary method for obtaining all ribosome-associated RNA expressed in a given cell type leads directly from this identification of cell type-specific promoters, in which overexpression of an epitope-tagged ribosomal protein (referred to as TRAP or RiboTag methods) under the control of one such cell type-specific promoter allows for purification by immunoprecipitation of the transcripts bound by the polyribosome in the desired cells 58 . An added benefit of the TRAP approach that results from labeling of the ribosomal protein is the presence of a strong immunoreactive signal in the nucleoli of the target cell types. This enables purification by fluorescenceactivated nuclei sorting of target nuclei for assessment of DNA and nascent RNA transcription in the specific cell type of interest, as well as proteomic analysis of histone modifications or transcription factor binding 120, 121 .
The primary advantage of the TRAP approach is the elimination of the need to purify cells; instead, all cells are lysed and processed, regardless of cell type, and specificity is achieved through immunoprecipitation. This technique has several clear benefits, including increased reproducibility between experiments, high yields of RNA for sequencing and, most importantly, the fact that the method performs equally well on neurons as it does on any other cell type. In addition, TRAP benefits an integrative multimodal analysis, in that the transcripts that are captured are actively engaged by the polyribosome, and therefore it is reasonable to expect their abundances to be a better proxy for protein levels than total cellular RNA.
Related immunoaffinity-based methods may be applicable to other types of organelles from specific neuronal cell types or other types of subcellular compartments of neurons, including synapses 111, 122, 123 . The utility of these methods is exemplified in a study in which transgenic mice containing both Flag-tagged and Myc-tagged DARPP-32 (also called PPPR1B) were used to study phosphorylation by protein kinase A in intermixed D1 receptor-containing direct-pathway and D2 receptor-containing indirect-pathway neurons, respectively, of the striatum 124 . The ability to isolate DARPP-32 by immunoprecipitation of either epitope-tagged protein after drug treatment provides a completely internally consistent mechanism to assess the effect of the drug in these two cell types. Thanks to the vastly increased resolving power of this approach, it was revealed that after cocaine administration, DARPP-32 phosphorylation is increased in D1-receptor neurons but is almost equally decreased in D2-receptor neurons 124 .
Despite these applications, the direct utility of immunoaffinity or TRAP methods for whole-proteome analysis is currently somewhat more limited than whole-genome or whole-transcriptome profiling. Perhaps one of the more immediate ways in which proteomics will benefit is by the creation of fully quantitative, cell type-specific transcriptomes for all amenable cells of the CNS. Moreover, RNA-seq TRAP data sets could be exploited to statistically deconvolute proteomic signals obtained from comparable tissues and, in a subset of the genes, may even be predictive of protein abundance. TRAPpurified RNAs are also directly compatible with the ribosome footprinting protocol, allowing for cell-type specificity in determinations of translational efficiency.
The principal disadvantage of the TRAP methodologies in studies of human tissues is the required genetic modification of the ribosomal protein by the GFP-tagged bacterial artificial chromosome transgene. For application to human neurobiology, it may become possible to exploit studies in genetically tractable rodent models to identify proteins at the plasma membrane of specific neuronal subtypes. Use of such cell-surface markers could then enable cell type-specific analyses of RNA and protein without the need for genetic modification and, combined with traditional methods of tissue dissection, may provide an excellent avenue to characterize and monitor RNA and protein
Box 1 An ideal integrated multi-omic analysis
Such an analysis would exploit information garnered at each stage of the gene-expression process to improve the overall utility of results obtained from RNA and protein profiling (Fig. 1) . Information regarding genomic variants in a given sample or individual can be used to create a personalized genome for that individual. These homozygous and heterozygous variants are incorporated in transcriptomic analysis by RNA-seq and enable the detection of allelic imbalance (ASE), in addition to information relating to alternative splicing and RNA editing (RDDs). This cascade of information in a given sample aids in the analysis of mass-spectrometry spectra, in which peptides may be identified that support or refute the presence of nonsynonymous alternative-splicing, RDD and ASE events. From the relative abundances of these peptides, it is possible to compare isoform abundance and allelic imbalance with the values estimated at the RNA level, allowing inferences to be made based on the proteomic data, such as the presence or absence of a particular protein isoform.
npg r e v i e w expression in tandem from a single cell type in specific regions of the brain. For these surface proteins, it may also be possible to identify extracellular domains, receptors and ion channels that display specific patterns of expression that could be future targets for small molecules or drugs. Such an approach would thus have the power to enable truly integrative, specific and biologically meaningful analyses of the mammalian CNS.
A perspective on the future of proteomics in neuroscience The ultimate goal of neuroproteomics is to identify and quantify the complete set of proteins in the CNS, understand their interactions and relationships to RNA abundance, identify PTMs and define specific marker proteins, especially at the plasma membrane, that can discriminate between a large number of cell types and allow for targeting by small molecules. Analysis of single cells and single cell types may soon define sets of RNAs and proteins that are capable, either individually or in combination, of this discrimination and produce targets for in situ hybridization imaging and other functional anatomical annotations of the brain. This advance will provide the mechanism for relating the molecular profiles of specific neuronal cell types to their positions and connectivities within the developing brain. Cataloging this connectivity will in turn provide the anatomical framework with which to interpret the internal dynamics of the as-yet unknown number of neuronal cell types. Promising advances have already been made in model organisms such as the mouse, but this approach must be applied across species before we are able to understand how protein regulation is negatively affected by developmental disorders, as well as the neuropathology of degenerative diseases and aging.
For the idealization of cell type-specific proteome profiling to be realized, there will need to be improvements in not only massspectrometry technology and reduced sample input requirements but also the analytical methods by which isoforms are identified, quantified and integrated with existing functional genomics data sets and related spatiotemporal atlases. Multimodal functional genomic analyses can be substantially enhanced with deep integration of proteomic data. With the current resources being allocated to research into the human CNS through the Brain Initiative, there is a fantastic opportunity for protein-level information to be obtained that substantially improves our understanding of the brain's development and functional anatomy. Modeling the circuitry of the brain can only ever be a realistic goal when there exists a comprehensive understanding of its constituent parts, including a much more precise definition of the large number of neuronal cells based on both their connectivities and their internal proteomes.
